BDTX — BLACK DIAMOND THERAPEUTICS I
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About BLACK DIAMOND THERAPEUTICS I (BDTX)
BLACK DIAMOND THERAPEUTICS I (BDTX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1M. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in BDTX
How many top investors track BDTX
A small number of top investors own this.
BDTX Ownership Composition
How BLACK DIAMOND THERAPEUTICS I is held across tracked investor types, based on reported 13F positions.
- Other88.0%
- Hedge Funds12.0%
Tracked investors reporting BDTX
- Ken GriffinMar 31, 2026Citadel AdvisorsShares604.6KValue$1.3M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares135KValue$287.5K% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares101KValue$215.1K% Portfolio0.00%
Recent activity
- $720.6KFeb 17, 2026
- $287.5KMay 15, 2026
- New$478.1KFeb 17, 2026
- New$1.3MMay 15, 2026
- New$215.1KMay 15, 2026
Frequently asked questions
- How many institutional investors hold BDTX?
- 3 tracked institutional investors disclosed a position in BDTX (BLACK DIAMOND THERAPEUTICS I) in their most recent 13F filing.
- Who is the largest institutional holder of BDTX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in BDTX, valued at $1M.
- Did institutional ownership of BDTX increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 fully exited BDTX.
- Where does this BDTX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.